Literature DB >> 32040552

Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia.

Victoria M Smith1,2, Oliver Lomas3, Donna Constantine4, Lianne Palmer3, Anna H Schuh5,6, David Bruce3,5,6, Oksana Gonchar2, Salvador Macip1,2, Sandrine Jayne2, Martin J S Dyer2, Toby A Eyre3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32040552      PMCID： PMC7013268          DOI： 10.1182/bloodadvances.2019000917

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  14 in total

1.  Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Authors:  Matthew S Davids; Andrew W Roberts; John F Seymour; John M Pagel; Brad S Kahl; William G Wierda; Soham Puvvada; Thomas J Kipps; Mary Ann Anderson; Ahmed Hamed Salem; Martin Dunbar; Ming Zhu; Franklin Peale; Jeremy A Ross; Lori Gressick; Monali Desai; Su Young Kim; Maria Verdugo; Rod A Humerickhouse; Gary B Gordon; John F Gerecitano
Journal:  J Clin Oncol       Date:  2017-01-17       Impact factor: 44.544

2.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

3.  Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Authors:  Stephan Stilgenbauer; Barbara Eichhorst; Johannes Schetelig; Steven Coutre; John F Seymour; Talha Munir; Soham D Puvvada; Clemens-Martin Wendtner; Andrew W Roberts; Wojciech Jurczak; Stephen P Mulligan; Sebastian Böttcher; Mehrdad Mobasher; Ming Zhu; Monali Desai; Brenda Chyla; Maria Verdugo; Sari Heitner Enschede; Elisa Cerri; Rod Humerickhouse; Gary Gordon; Michael Hallek; William G Wierda
Journal:  Lancet Oncol       Date:  2016-05-10       Impact factor: 41.316

4.  The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.

Authors:  András Kotschy; Zoltán Szlavik; James Murray; James Davidson; Ana Leticia Maragno; Gaëtane Le Toumelin-Braizat; Maïa Chanrion; Gemma L Kelly; Jia-Nan Gong; Donia M Moujalled; Alain Bruno; Márton Csekei; Attila Paczal; Zoltán B Szabo; Szabolcs Sipos; Gábor Radics; Agnes Proszenyak; Balázs Balint; Levente Ondi; Gábor Blasko; Alan Robertson; Allan Surgenor; Pawel Dokurno; Ijen Chen; Natalia Matassova; Julia Smith; Christopher Pedder; Christopher Graham; Aurélie Studeny; Gaëlle Lysiak-Auvity; Anne-Marie Girard; Fabienne Gravé; David Segal; Chris D Riffkin; Giovanna Pomilio; Laura C A Galbraith; Brandon J Aubrey; Margs S Brennan; Marco J Herold; Catherine Chang; Ghislaine Guasconi; Nicolas Cauquil; Fabien Melchiore; Nolwen Guigal-Stephan; Brian Lockhart; Frédéric Colland; John A Hickman; Andrew W Roberts; David C S Huang; Andrew H Wei; Andreas Strasser; Guillaume Lessene; Olivier Geneste
Journal:  Nature       Date:  2016-10-19       Impact factor: 49.962

5.  High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.

Authors:  C E Dearden; E Matutes; B Cazin; G E Tjønnfjord; A Parreira; B Nomdedeu; P Leoni; F J Clark; D Radia; S M Rassam; T Roques; N Ketterer; V Brito-Babapulle; M J Dyer; D Catovsky
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

6.  High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Michael A Teitell; Marina Konopleva; Farhad Ravandi; Ryuji Kobayashi; Dan Jones
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

7.  First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.

Authors:  Bernd Boidol; Christoph Kornauth; Emiel van der Kouwe; Nicole Prutsch; Lukas Kazianka; Sinan Gültekin; Gregor Hoermann; Marius E Mayerhoefer; Georg Hopfinger; Alexander Hauswirth; Michael Panny; Marie-Bernadette Aretin; Bernadette Hilgarth; Wolfgang R Sperr; Peter Valent; Ingrid Simonitsch-Klupp; Richard Moriggl; Olaf Merkel; Lukas Kenner; Ulrich Jäger; Stefan Kubicek; Philipp B Staber
Journal:  Blood       Date:  2017-09-27       Impact factor: 22.113

8.  Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.

Authors:  Meike Vogler; Michael Butterworth; Aneela Majid; Renata J Walewska; Xiao-Ming Sun; Martin J S Dyer; Gerald M Cohen
Journal:  Blood       Date:  2008-11-13       Impact factor: 22.113

9.  Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.

Authors:  Toby A Eyre; Harriet S Walter; Sunil Iyengar; George Follows; Matthew Cross; Christopher P Fox; Andrew Hodson; Josh Coats; Santosh Narat; Nick Morley; Martin J S Dyer; Graham P Collins
Journal:  Haematologica       Date:  2018-09-06       Impact factor: 9.941

10.  Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.

Authors:  Ryohei Kozaki; Meike Vogler; Harriet S Walter; Sandrine Jayne; David Dinsdale; Reiner Siebert; Martin J S Dyer; Toshio Yoshizawa
Journal:  Cancers (Basel)       Date:  2018-04-23       Impact factor: 6.639
View more
  5 in total

1.  Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.

Authors:  Paul J Hampel; Sameer A Parikh; Timothy G Call; Mithun V Shah; N Nora Bennani; Aref Al-Kali; Kari G Rabe; Yucai Wang; Eli Muchtar; Jose F Leis; Saad S Kenderian; Amber B Koehler; Susan M Schwager; Susan L Slager; Neil E Kay; Curtis A Hanson; Daniel L Van Dyke; Min Shi; Wei Ding
Journal:  Blood Cancer J       Date:  2021-03-02       Impact factor: 11.037

Review 2.  MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.

Authors:  Arnold Bolomsky; Meike Vogler; Murat Cem Köse; Caroline A Heckman; Grégory Ehx; Heinz Ludwig; Jo Caers
Journal:  J Hematol Oncol       Date:  2020-12-11       Impact factor: 17.388

3.  Hijacking the Pathway: Perspectives in the Treatment of Mature T-cell Leukemias.

Authors:  Linus Wahnschaffe; Marco Herling
Journal:  Hemasphere       Date:  2021-06-01

Review 4.  The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine.

Authors:  Isacco Ferrarini; Antonella Rigo; Carlo Visco
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

5.  Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis

Authors:  Sheila Bohler; Sehar Afreen; Juncal Fernandez-Orth; Eva-Maria Demmerath; Christian Molnar; Ying Wu; Julia Miriam Weiss; Venugopal Rao Mittapalli; Lukas Konstantinidis; Hagen Schmal; Mirjam Kunze; Miriam Erlacher
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.